Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.
Xbrane Biopharma AB reported a profitable first half of 2025, with significant revenue growth and a strengthened financial position due to strategic transactions and a directed share issue. The company is advancing its biosimilar candidate Lucentis® in the US regulatory process and has initiated a clinical study for Xdivane™, positioning itself for future growth and market expansion.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a biotechnology company specializing in the development and commercialization of biosimilars. The company’s primary focus is on providing cost-effective biological drugs, with a significant presence in the European market and ongoing regulatory processes in the US.
Average Trading Volume: 14,768,446
Technical Sentiment Signal: Sell
Current Market Cap: SEK438.2M
For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.